Celebrating Success: Major Achievement in COMBACTE-CARE

Read more
combacte-cdi

Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile

Background:

Until recently, metronidazole was the first-line treatment for Clostridioides difficile infection and it is still commonly used. Though resistance has been reported due to the plasmid pCD-METRO, this does not explain all cases.

Objectives:

To identify factors that contribute to plasmid-independent metronidazole resistance of C. difficile.

Methods:

Here, we investigate resistance to metronidazole in a collection of clinical isolates of C. difficile using a combination of antimicrobial susceptibility testing on different solid agar media andWGS of selected isolates.

Results:

We find that nearly all isolates demonstrate a haem-dependent increase in the MIC of metronidazole, which in some cases leads to isolates qualifying as resistant (MIC >2 mg/L). Moreover, w e find an SNP in the haem-responsive gene hsmA, which defines a metronidazole-resistant lineage of PCR ribotype 010/MLST ST15 isolates that also includes pCD-METRO-containing strains.

Conclusions:

Our data demonstrate that haem is crucial for medium-dependent metronidazole resistance in C. difficile.

To JAC
22/02/2023

Impact of testing on Clostridioides difficile infection in hospitals across Europe: A mathematical model

23/01/2023

Clostridioides difficile infection (CDI): A pan-European multi-center cost and resource utilization study, results from the Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI)

27/12/2022

European survey on the current surveillance practices, management guidelines, treatment pathways and heterogeneity of testing of Clostridioides difficile, 2018–2019: results from The Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI)